Document is current
Any future updates will be listed below
-
Authors
Javorniczky, Nora Rebeka
Grishina, Olga
Hund, Inga
Pantic, Milena
Pfeifer, Dietmar
Schmoor, Claudia
Thomas, Johanna
Duyster, Justus
Becker, Heiko
Lübbert, Michael
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FOR2674 A05, 192904750)
German Federal Ministry of Education and Research (BMBF, Clinical Trials Program (01KG0913)
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Received: 13 September 2023
Accepted: 3 November 2023
First Online: 28 November 2023
Declarations
:
: The DECIDER study was approved by the central ethics committee (University of Freiburg). The patient’s written consent to participate in this clinical trial and its translational research program was obtained before any study-specific procedures occurred. This trial was registered at ClinicalTrials.gov identifier: NCT00867672.
: C.Sch. had a consulting and advisory role for Roche and Novartis. C. Sch. received research funding from Boehringer Ingelheim (Inst) and from Neovii Biotech (Inst) Novartis. H.B. received honoraria from Abbvie, BMS, Pierre Fabre Pharma, Servier, MSD, Novartis, Lilly and GSK. M.L. had an advisory role for Astex Pharmaceuticals, Janssen and Otsuka. M.L. received research funding from Janssen and research support with study drug from Cheplapharm (ATRA) and Janssen (decitabine). The remaining authors declare no competing financial interests.
